UIPATH INC - CLASS A (PATH)

US90364P1057 - Common Stock

13.395  -0.5 (-3.56%)

Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to PATH. PATH was compared to 279 industry peers in the Software industry. PATH has a great financial health rating, but its profitability evaluates not so good. PATH is valied quite expensively at the moment, while it does show a decent growth rate.



Quickly go to:

3

1. Profitability

1.1 Basic Checks

PATH had positive earnings in the past year.
PATH had a positive operating cash flow in the past year.
In the past 5 years PATH always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: PATH reported negative operating cash flow in multiple years.

1.2 Ratios

PATH has a Return On Assets of -4.16%. This is comparable to the rest of the industry: PATH outperforms 50.54% of its industry peers.
PATH has a Return On Equity (-6.13%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -4.16%
ROE -6.13%
ROIC N/A
ROA(3y)-11.83%
ROA(5y)-29.69%
ROE(3y)-16.3%
ROE(5y)-67.01%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 83.98%, PATH belongs to the top of the industry, outperforming 90.68% of the companies in the same industry.
PATH's Gross Margin has improved in the last couple of years.
PATH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 83.98%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.57%
GM growth 5Y3.54%

More info and screens

8

2. Health

2.1 Basic Checks

PATH does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PATH has been increased compared to 1 year ago.
There is no outstanding debt for PATH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

PATH has an Altman-Z score of 5.25. This indicates that PATH is financially healthy and has little risk of bankruptcy at the moment.
PATH's Altman-Z score of 5.25 is fine compared to the rest of the industry. PATH outperforms 62.72% of its industry peers.
There is no outstanding debt for PATH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 5.25
ROIC/WACCN/A
WACC10.8%

2.3 Liquidity

A Current Ratio of 3.60 indicates that PATH has no problem at all paying its short term obligations.
PATH has a Current ratio of 3.60. This is in the better half of the industry: PATH outperforms 78.85% of its industry peers.
A Quick Ratio of 3.60 indicates that PATH has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.60, PATH is in the better half of the industry, outperforming 78.85% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.6
Quick Ratio 3.6

More info and screens

6

3. Growth

3.1 Past

PATH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 27.50%, which is quite impressive.
Looking at the last year, PATH shows a very strong growth in Revenue. The Revenue has grown by 20.42%.
Measured over the past years, PATH shows a very strong growth in Revenue. The Revenue has been growing by 54.52% on average per year.
EPS 1Y (TTM)27.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-55.56%
Revenue 1Y (TTM)20.42%
Revenue growth 3Y29.12%
Revenue growth 5Y54.52%
Sales Q2Q%10.07%

3.2 Future

The Earnings Per Share is expected to decrease by -0.74% on average over the next years.
Based on estimates for the next years, PATH will show a quite strong growth in Revenue. The Revenue will grow by 12.48% on average per year.
EPS Next Y-24.98%
EPS Next 2Y-8.95%
EPS Next 3Y-0.05%
EPS Next 5Y-0.74%
Revenue Next Year10.59%
Revenue Next 2Y10.84%
Revenue Next 3Y11.34%
Revenue Next 5Y12.48%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 26.26 indicates a quite expensive valuation of PATH.
Based on the Price/Earnings ratio, PATH is valued a bit cheaper than the industry average as 75.63% of the companies are valued more expensively.
PATH is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 29.20, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 29.92 indicates a quite expensive valuation of PATH.
68.82% of the companies in the same industry are more expensive than PATH, based on the Price/Forward Earnings ratio.
PATH's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 23.84.
Industry RankSector Rank
PE 26.26
Fwd PE 29.92

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, PATH is valued cheaper than 83.87% of the companies in the same industry.
Industry RankSector Rank
P/FCF 22.54
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.95%
EPS Next 3Y-0.05%

More info and screens

0

5. Dividend

5.1 Amount

PATH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

UIPATH INC - CLASS A

NYSE:PATH (11/12/2024, 1:24:09 PM)

13.395

-0.5 (-3.56%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap7.37B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE 26.26
Fwd PE 29.92
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -4.16%
ROE -6.13%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 83.98%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 3.6
Quick Ratio 3.6
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)27.5%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-24.98%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)20.42%
Revenue growth 3Y29.12%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y